Brief: Bellus Health Announces Positive Topline Results From Its Phase 2B Soothe Trial Of Blu-5937 For Treatment Of Refractory Chronic Cough

BELLUS Health

13/12/2021 12:24

Dec 13 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS
PHASE
2B SOOTHE TRIAL OF BLU-5937 FOR TREATMENT OF REFRACTORY CHRONIC
COUGH
    * BELLUS HEALTH - BLU-5937 WAS WELL-TOLERATED WITH A LOW
RATE OF
TASTE-RELATED ADVERSE EVENTS (≤6.5%)
    * BELLUS HEALTH - TO REQUEST END OF PHASE 2 MEETING WITH FDA
THAT
IS EXPECTED IN 2Q 2022 TO DISCUSS PHASE 3 PROGRAM, EXPECTED TO
START 2H 2022

Source text for Eikon:  ID:nBw4H51gYa 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))